Zafgen, Inc. (ZFGN)
(Delayed Data from NSDQ)
$2.65 USD
+0.09 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Larimar Therapeutics, Inc. [ZFGN]
Reports for Purchase
Showing records 21 - 40 ( 45 total )
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; Updates on ZGN-1061/T2D Clinical Hold Anticipated in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
We are initiating coverage of Zafgen, Inc. (ZFGN) with a Buy rating and $8 PT.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
ZGN-1061 (1.8 mg) Phase 2 Results for T2D Better Than Expected
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Clinical Hold Focus on Target: Guilty Until Proven Innocent
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Strong Cash Position; Next: ZGN-1061 Phase 2 PoC Data in Early 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - 2018 Wedbush PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials- Cash into Q1:20 Supports Next Generation MetAP2i
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Initiate OP; Potent, Safer NextGen MetAP2i May Reach Blockbuster Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Larimar Therapeutics, Inc.
Industry: Medical - Drugs
We are dropping coverage of ZFGN shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.